Wednesday, July 16, 2025

Researchers grow 400+ brain cell types—a leap for Alzheimer’s and Parkinson’s research

Nerve cells are not just nerve cells. Depending on how finely we distinguish, there are several hundred to several thousand different types of nerve cell in the human brain according to the latest calculations. These cell types vary in their function, in the number and length of their cellular appendages, and in their interconnections. They emit different neurotransmitters into our synapses and, depending on the region of the brain - for example, the cerebral cortex or the midbrain - different cell types are active.

When scientists produced nerve cells from stem cells in Petri dishes for their experiments in the past, it was not possible to take their vast diversity into account. Until now, researchers had only developed procedures for growing a few dozen different types of nerve cell in vitro. They achieved this using genetic engineering or by adding signalling molecules to activate particular cellular signalling pathways. However, they never got close to achieving the diversity of hundreds or thousands of different nerve cell types that actually exists.

"Neurons derived from stem cells are frequently used to study diseases. But up to now, researchers have often ignored which precise types of neuron they are working with," says Barbara Treutlein, Professor at the Department of Biosystems Science and Engineering at ETH Zurich in Basel. However, this is not the best approach to such work. "If we want to develop cell culture models for diseases and disorders such as Alzheimer's, Parkinson's and depression, we need to take the specific type of nerve cell involved into consideration."

Systematic screening was the key to success

Treutlein and her team have now successfully produced over 400 different types of nerve cell. In doing so, the scientists have paved the way for more precise basic neurological research with cell culture experiments.

The ETH researchers achieved this by working with a culture of human induced pluripotent stem cells that had been generated from blood cells. In these cells, they used genetic engineering to activate certain neuronal regulator genes and treated the cells with various morphogens, a special class of signalling molecules. Treutlein and her team took a systematic approach, using seven morphogens in different combinations and concentrations in their screening experiments. This resulted in almost 200 different sets of experimental conditions.

Morphogens

Morphogens are messengers that are known from research into embryonic development. They are not distributed uniformly within an embryo but occur in a variety of concentrations forming spatial patterns. In this way, they define the position of cells within the embryo, for example whether a cell is near the body axis or in the back, abdomen, head or torso. Accordingly, morphogens help to determine what grows where in the embryo.

The researchers used various analyses to prove that they had produced over 400 different types of nerve cell in their experiment. They examined the RNA (and therefore genetic activity) at the level of individual cells, as well as the external appearance of cells and their function: for example, which type of cell appendage they had in which quantities and which electric nerve impulses they emitted.

The researchers then compared their data with information from databases of neurons from the human brain. By doing this, they were able to identify the types of nerve cell that had been created, such as those found in the peripheral nervous system or brain cells and the part of the brain they come from, whether they perceive pain, cold or movement, and so on.

In-vitro neurons for active ingredient research

Treutlein clarifies that they are still a long way off producing all types of nerve cell that exist in vitro. Nonetheless, the researchers now have access to a much larger number of different cell types than they had before.

They would like to use in-vitro nerve cells to develop cell culture models for studying serious neurological conditions, including schizophrenia, Alzheimer's, Parkinson's, epilepsy, sleep disorders and multiple sclerosis. Cell culture models of this kind are also of great interest in pharmaceutical research for testing the effects of new active compounds in cell cultures without animal testing, with the ultimate aim of one day being able to cure these conditions.

In the future, the cells could also be used for cell replacement therapy, which involves replacing sick or dead nerve cells in the brain with new human cells.

But there is a challenge to overcome before this can happen: the researchers often produced a mixture of multiple different types of nerve cell in their experiments. They are now working to optimise their method so that each experimental condition only produces one specific cell type. They already have some initial ideas as to how this might be achieved.

Journal Reference:

  1. Hsiu-Chuan Lin, Jasper Janssens, Benedikt Eisinger, Philipp Hornauer, Ann-Sophie Kroell, Malgorzata Santel, Maria Pascual-Garcia, Ryoko Okamoto, Kyriaki Karava, Zhisong He, Marthe Priouret, Manuel Schröter, J. Gray Camp, Barbara Treutlein. Human neuron subtype programming via single-cell transcriptome-coupled patterning screens. Science, 2025; 389 (6756) DOI: 10.1126/science.adn6121 

Courtesy:
ETH Zurich. "Researchers grow 400+ brain cell types—a leap for Alzheimer’s and Parkinson’s research." ScienceDaily. ScienceDaily, 12 July 2025. <www.sciencedaily.com/releases/2025/07/250711224316.htm>. 

 

Tuesday, July 15, 2025

Hormone therapy supercharges tirzepatide, unleashing major weight loss after menopause

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone, according to a study presented at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

"These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women," said Regina Castaneda, M.D., research fellow for the Division of Endocrinology at the Mayo Clinic in Jacksonville, Fla. "Previous studies of the medication semaglutide found similar results. Achieving these outcomes with a second obesity medication may indicate a broader efficacy trend for pairing these two classes of medications."

Menopause-related hormonal changes often result in increased abdominal fat, decreased muscle mass and altered energy expenditure that leads to weight gain and puts millions of women at risk for developing heart disease and other serious health issues.

To confirm the hypothesis that concurrent menopause hormone therapy enhances the effectiveness of tirzepatide for weight loss in postmenopausal women, researchers conducted a real-world study using the electronic medical records of 120 postmenopausal women over a median duration of 18 months. The study included two cohorts: 40 women using menopause hormone therapy concurrently with tirzepatide and 80 women using tirzepatide alone.

The results showed superior total body weight loss percentage for women using tirzepatide plus menopause hormone therapy (17%) compared to those using tirzepatide alone (14%). In addition, a higher percentage of menopause hormone therapy users (45%) also achieved at least 20% total body weight loss, compared to 18% of menopause hormone therapy non-users.

"The information garnered through this new study provides important insights to develop more effective and personalized weight management interventions to reduce a postmenopausal woman's risk of overweight and obesity-related health complications," said Maria Daniela Hurtado Andrade, M.D., Ph.D., assistant professor of medicine and consultant for the Division of Endocrinology at the Mayo Clinic. "This study underscores the urgent need for further research to better understand how obesity medications and menopause hormone therapy work together. Gaining this knowledge could greatly improve the health and well-being of millions of postmenopausal women. It also points to the need for better strategies to make these treatments more accessible and available to those who need them."

This research was funded by the National Institutes of Health Bridging Interdisciplinary Careers in Women's Health Research Grant and the Mayo Clinic Center for Women's Health Research.

Citation:

The Endocrine Society. "Hormone therapy supercharges tirzepatide, unleashing major weight loss after menopause." ScienceDaily. ScienceDaily, 13 July 2025. <www.sciencedaily.com/releases/2025/07/250713031441.htm>.